A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
for
Overweight, Obesity
Location: Boston MA, Waltham MA, New Haven CT, Waterbury CT,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT07392190
Phase 3, Recruiting
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
for
Severe Hypertriglyceridemia
Location: Chicoutimi, Trois-Rivieres, Vancouver
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT07269210
Phase 2, Recruiting
Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease
for
Peripheral Arterial Disease
Location: Levis, Laval, Virginia Beach VA, Bowie MD, Camp Hill PA,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT07223593
Phase 3, Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
for
Overweight, Obesity
Location: New Bedford MA, Hamden CT, Bridgeport CT,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT07282600
Phase 3, Recruiting
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
for
Breast Neoplasms, Neoplasm Metastasis
Location: Summit NJ, Philadelphia PA, Cherry Hill NJ, Sewell NJ,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18+
Code: NCT07174336
Phase 3, Recruiting
A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)
for
Bipolar Disorder
Location: Watertown MA, Springfield MA, New Haven CT,
Sponsor: Eli Lilly and Company
Sex: All
Age: 18 - 70+
Code: NCT07286175
Phase 2, Recruiting
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer